Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL

por Duell, J, Dittrich, M, Bedke, T, Mueller, T, Eisele, F, Rosenwald, A, Rasche, L, Hartmann, E, Dandekar, T, Einsele, H, Topp, M S
Publicado 2017

Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma

por Besse, A, Stolze, S C, Rasche, L, Weinhold, N, Morgan, G J, Kraus, M, Bader, J, Overkleeft, H S, Besse, L, Driessen, C
Publicado 2018

P44 DETECTION OF SOLUBLE BCMA IN TEARS OF MM PATIENTS TREATED WITH BELANTAMAB MAFODOTIN

por Munawar, U., Theuersbacher, J., Haertle, L., Zhou, X., Han, S., Regensburger, A., Mersi, J., Bittrich, M., Seifert, F., Haider, M.S., Nerreter, S., Vogt, C., Teufel, E., Einsele, H., Rasche, L., Kampik, D., Kortüm, K.M.
Publicado 2023

PB1980: MULTIPLE MYELOMA: ADOPTING MRD BY NEXT GENERATION FLOW CYTOMETRY (NGF) AND FUNCTIONAL IMAGING GUIDED CONSOLIDATION INTO CLINICAL ROUTINE

por Boeckle, D., Tabares, P., Zhou, X., Schimanski, S., Steinhardt, M. J., Bittrich, M., Seebacher, E., Ulbrich, M., Wilnit, A., Metz, C., Heidemeier, A., Bley, T., Werner, R., Buck, A., Einsele, H., Kortüm, M., Beilhack, A., Rasche, L.
Publicado 2022

Progressive multifocal leukoencephalopathy in a patient post allo-HCT successfully treated with JC virus specific donor lymphocytes

por Steinhardt, M. J., Wiercinska, E., Pham, M., Grigoleit, G. U., Mazzoni, A., Da-Via, M., Zhou, X., Meckel, K., Nickel, K., Duell, J., Krummenast, F. C., Kraus, S., Hopkinson, C., Weissbrich, B., Müllges, W., Stoll, G., Kortüm, K. M., Einsele, H., Bonig, H., Rasche, L.
Publicado 2020

P23 EMAGINE/CARTITUDE-6: A RANDOMIZED PHASE 3 STUDY OF DVRD FOLLOWED BY CILTACABTAGENE AUTOLEUCEL VERSUS DVRD FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT IN TRANSPLANT-ELIGIBLE PAT...

por Broijl, A., San-Miguel, J., Suzuki, K., Krishnan, A., van de Donk, N., Cook, G., Jakubowiak, A., Madduri, D., Afifi, S., Stevens, A., Schecter, J., Deraedt, W., Kuppens, S., Mistry, P., Pacaud, L., Boccadoro, M., Gay, F., Mina, R., Rasche, L., Moreau, P., Mateos, M., Einsele, H., Sonneveld, P.
Publicado 2023

P45 HIGH-DOSE CARFILZOMIB ACHIEVES SUPERIOR ANTI-TUMOR ACTIVITY OVER LOW-DOSE AND RECAPTURES RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RESISTANT TO LOW-DOSE CARFILZOMIB BY C...

por Zhou, X., Besse, A., Peter, J., Steinhardt, M. J., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Xiao, X., Hornburger, H., Haertle, L., Mendez Lopez, M., Munawar, U., Riedel, A., Han, S., Maurits, E., Overkleeft, H. S., Florea, B., Einsele, H., Kortüm, K. M., Driessen, C., Besse, L., Rasche, L.
Publicado 2023

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing

por Rasche, L., Chavan, S. S., Stephens, O. W., Patel, P. H., Tytarenko, R., Ashby, C., Bauer, M., Stein, C., Deshpande, S., Wardell, C., Buzder, T., Molnar, G., Zangari, M., van Rhee, F., Thanendrarajan, S., Schinke, C., Epstein, J., Davies, F. E., Walker, B. A., Meissner, T., Barlogie, B., Morgan, G. J., Weinhold, N.
Publicado 2017

P52 RISK STRATIFICATION COMBINING SKY92 GENE EXPRESSION PROFILING AND TRADITIONAL FISH IN MULTIPLE MYELOMA: THE FIRST PROSPECTIVE EVIDENCE IN THE R2-ISS ERA

por Zhou, X., Hofmann, A., Vogt, C., Nerreter, S., Teufel, E., Stanojkovska, E., Truger, M., Engel, B., Xiao, X., Eisele, F., Weis, P., Barcic, A., Peter, J., Riedhammer, C., Steinhardt, M. J., Hornburger, H., Han, S., Haertle, L., Munawar, U., Mersi, J., Haferlach, C., Einsele, H., Kortüm, K. M., Rasche, L.
Publicado 2023

Combination of Flow Cytometry and Functional Imaging for Monitoring of Residual Disease in Myeloma

por Rasche, L, Alapat, D, Kumar, M, Gershner, G, McDonald, J, Wardell, C.P, Samant, R, Van Hemert, R, Epstein, J, Williams, A.F, Thanendrarajan, S, Schinke, C, Bauer, M, Ashby, C, Tytarenko, R.G, van Rhee, F, Walker, B.A, Zangari, M, Barlogie, B, Davies, F.E, Morgan, G.J, Weinhold, N
Publicado 2018

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP...

por van de Donk, N., Rasche, L., Touzeau, C., Chari, A., Schinke, C., Minnema, M., Berdeja, J., Oriol, A., Rodriguez-Otero, P., Askari, E., Mateos, M., Costa, L., Caers, J., Krishnan, A., Vishwamitra, D., Ma, J., Qin, X., Gries, K.S., Kato, K., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J., Heuck, C., Moreau, P., San-Miguel, J.
Publicado 2023

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)...

por Minnema, M.C., Chari, A., Touzeau, C., Schinke, C., Berdeja, J., Oriol, A., van, de Donk N., Otero, P.R., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., Rasche, L., Krishnan, A., Vishwamitra, D., Ma, X., Qin, X., Gries, K.S., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J.D., Heuck, C., Miguel, J.S., Moreau, P.
Publicado 2023

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker

por Chavan, S S, He, J, Tytarenko, R, Deshpande, S, Patel, P, Bailey, M, Stein, C K, Stephens, O, Weinhold, N, Petty, N, Steward, D, Rasche, L, Bauer, M, Ashby, C, Peterson, E, Ali, S, Ross, J, Miller, V A, Stephens, P, Thanendrarajan, S, Schinke, C, Zangari, M, van Rhee, F, Barlogie, B, Mughal, T I, Davies, F E, Morgan, G J, Walker, B A
Publicado 2017